Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -11.63
- Piotroski Score 2.00
- Grade Buy
- Symbol (VYNE)
- Company VYNE Therapeutics Inc.
- Price $3.19
- Changes Percentage (1.11%)
- Change $0.04
- Day Low $3.11
- Day High $3.25
- Year High $4.48
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $5.75
- High Stock Price Target $5.75
- Low Stock Price Target $5.75
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.13
- Trailing P/E Ratio -1.99
- Forward P/E Ratio -1.99
- P/E Growth -1.99
- Net Income $-28,452,000
Income Statement
Quarterly
Annual
Latest News of VYNE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully
Investors are drawn to unprofitable companies due to growth potential. Analyzing VYNE Therapeutics' cash burn and runway, it is crucial to monitor its cash reserves and revenue growth for investment d...
By Yahoo! Finance | 1 month ago -
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year
Insiders at VYNE Therapeutics have been net buyers over the past year, indicating confidence in the company's future. Lead Independent Director Patrick LePore made the biggest insider purchase. While ...
By Yahoo! Finance | 3 months ago
